Ocular insert apparatus and methods

• US 9,937,073 B2
• Filed: 01/20/2015
• Issued: 04/10/2018
• Est. Priority Date: 06/01/2010
• Status: Active Grant

• Current Assignee: ForSight VISION5, Inc. (Abbvie Incorporated)
• Original Assignee: ForSight VISION5, Inc. (Abbvie Incorporated)
• Inventors: de Juan, Jr., Eugene, Alster, Yair, Reich, Cary J., Macfarlane, K. Angela, Chang, Janelle, Boyd, Stephen, Sierra, David, Alejandro, Jose D., Sutton, Douglas, Gould, Alexander J.
• Primary Examiner(s): SU, SUSAN SHAN
• Application Number:
  US14/600,505
• Publication Number:
  US 20150133878A1
• Time in Patent Office: 1,176 Days
• Field of Search: 604294, 604300
• CPC Class Codes: A61B 17/00234 for minimally invasive surgery A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61L 27/025 Other specific inorganic materials not covered by A61L27/04 - A61L27/12
• CPC Class Codes: A61L 27/16 obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

Claims

1. An ocular insert for delivering at least one therapeutic agent to an eye for an extended period of time, the insert comprising:

a supporting skeletal structure forming at least an arc of an annulus, the skeletal structure configured to be positioned on the eye outside the cornea of the eye and at least partially underneath at least one of the upper and lower eyelids;

an outer structure encapsulating at least a first portion of the skeletal structure along the arc, the outer structure supported by the skeletal structure, wherein the outer structure is of a durometer that is lower than a durometer of the skeletal structure; and

at least one therapeutic agent provided by the ocular insert;

wherein the ocular insert has a first shape prior to being positioned onto the eye, and the ocular insert conforms in situ after being positioned onto the eye for a period of time, and wherein, upon being removed from the eye, the ocular insert maintains a second shape that is different from the first shape, wherein the skeletal structure determines the first shape and the second shape of the ocular insert.

2. An ocular insert as in claim 1, wherein the second shape is a shape of at least a portion of an anterior surface of the eye.

3. An ocular insert as in claim 1, wherein the second shape is a shape of at least a portion of an anterior surface of the eye outside of the cornea.

4. An ocular insert as in claim 1, wherein the second shape is a shape of at least a region of a fornix of the eye.

5. An ocular insert as in claim 1, wherein the second shape is a shape of at least a portion of the bony orbit of the eye.

6. An ocular insert as in claim 1, wherein the ocular insert resists deflection away from the second shape.

7. An ocular insert as in claim 1, wherein the first shape is annular.

8. An ocular insert as in claim 1, wherein the first shape is positioned substantially within a first plane and the second shape at least partially extends outside of the first plane.

9. An ocular insert as in claim 1, wherein the skeletal structure comprises polypropylene.

10. An ocular insert as in claim 9, wherein the outer structure comprises a silicone material.

11. An ocular insert as in claim 10, wherein the silicone material comprises the at least one therapeutic agent.

12. An ocular insert as in claim 1, wherein only the outer structure comprises the at least one therapeutic agent.

13. An ocular insert as in claim 1, wherein the at least one therapeutic agent comprises a prostaglandin analogue.

14. An ocular insert as in claim 13, wherein the prostaglandin analogue comprises at least one of bimatoprost, latanoprost, travoprost, and tafluprost.

15. An ocular insert as in claim 1, wherein the at least one therapeutic agent is for lowering the intraocular pressure of the eye.

16. An ocular insert as in claim 1, wherein the insert comprises one or more haptics for assisting positioning the insert on the eye.

17. An ocular insert as in claim 1, wherein the skeletal structure comprises the at least one therapeutic agent provided by the ocular insert.

18. An ocular insert as in claim 1, wherein the outer structure comprises the at least one therapeutic agent provided by the ocular insert.

19. An ocular insert as in claim 1, wherein both the skeletal structure and the outer structure comprise the at least one therapeutic agent provided by the ocular insert.

20. An ocular insert as in claim 1, wherein the skeletal structure is formed of a material selected from the group consisting of polypropylene, nylon, PMMA, polycarbonate, polyethylene terepthalate, polyethylenes, and polyether ether ketone (PEEK).

21. An ocular insert as in claim 1, wherein the outer structure is formed of a silicone material, polyurethane material, or a hydrogel material.

22. An ocular insert as in claim 1, wherein the at least one therapeutic agent is configured to treat dry eye.

23. An ocular insert as in claim 22, wherein the at least one therapeutic agent is a lubricant or a surfactant.

24. An ocular insert as in claim 22, wherein the at least one therapeutic agent is selected from the group consisting of a non-pharmacologic agent, a lipid, a phospholipid, a fatty alcohol, a fatty acid, an oil, and a silicone oil.

25. An ocular insert as in claim 1, wherein the skeletal structure has a cross-sectional diameter of between about 0.05 mm and about 0.5 mm and the outer structure has a cross-sectional diameter of about 0.25 mm to about 1.5 mm.

26. An ocular insert as in claim 25, wherein the skeletal structure is comprised of polypropylene and has a cross-sectional diameter of between about 0.05 mm and about 0.5 mm and the second material is comprised of silicone and has a cross-sectional diameter of about 0.25 mm to about 1.5 mm.

27. An ocular insert as in claim 26, wherein the silicone has a durometer of at least about Shore A 10 to at least about Shore A 80.

28. An ocular insert as in claim 1, wherein the skeletal structure is formed to have a self-loading resistance to deflection within a range from about 0.005 N/mm to about 10 N/mm.

29. An ocular insert as in claim 1, wherein the skeletal structure is formed to have a first self-loading resistance to deflection between about 1 degree and about 60 degrees, wherein the first self-loading resistance to deflection comprises a deflection angle between a first portion of the skeletal structure and a second portion of the skeletal structure when the first portion is supported and held in place and the weight of the second portion deflects the skeletal structure.